1st Closed Scientific Expert Meeting of the Editorial Board

Lp(a) is an extremely atherogenic lipoprotein: Relevance to primary and secondary prevention 

November 19, 2024

Dr Gissette Reyes-Soffer, Columbia University, New York, USA, sets the scene for discussions about Lp(a) atherogenicity and its relevance to primary and secondary prevention.

Update on lipid lowering therapies: Zerlasiran

November 14, 2024

Professor Steven Nissen, Cleveland Clinic, Ohio, USA, reviews progress with the siRNA, zerlasiran, in early phase Lp(a) lowering clinical trials.

Update on lipid lowering therapies: Lepodisiran

Dr Ann Marie Navar, University of Texas Southwestern Medical Center, Dallas, USA, presents data from a Phase 1 ascending dose study of the siRNA, lepodisiran.

Update on lipid lowering therapies: Pelacarsen

Professor Steven Nissen, Cleveland Clinic, Ohio, USA, discusses Phase 2 data about the effects of the liver-targeted antisense oligonucleotide, pelacarsen, on Lp(a).

Update on lipid lowering therapies: Olpasiran

Dr Michelle O’Donoghue, Brigham and Women’s Hospital, Boston, USA, presents data on the siRNA, olpasiran, from the Phase 2 OCEAN(a) DOSE study.

The proinflammatory Lp(a) lipidome 

November 19, 2024

Dr Jeffrey Kroon, Amsterdam UMC, The Netherlands, dives deeper into the atherogenicity of Lp(a) with a focus on the pro-inflammatory lipidome.